Oral and Topical Spironolactone for Pattern Hair Loss: 2023 Systematic Review Research Summary
This is a plain-language summary of the original published research. We do not add conclusions or opinions of our own. This is not medical advice — consult a certified healthcare practitioner before making any decision.
Original research published in Clinical, Cosmetic and Investigational Dermatology, 2023
Oral and Topical Spironolactone for Pattern Hair Loss
Study conclusion
Systematic review of 7 studies covering 618 patients found both oral and topical spironolactone improved hair growth in pattern hair loss. Topical spironolactone had significantly fewer side effects than oral and was effective in both men and women. Combining spironolactone with minoxidil consistently produced better results than either treatment alone.
Strength of evidence
This was a systematic review without statistical pooling. The score is limited because the evidence base included studies of varying quality (only 2 were RCTs), total sample was 618 across 7 studies, and most evidence involved female patients. Topical spironolactone evidence is especially thin.
Who it applies to
Who was studied
618 patients across 7 studies (65 men, 553 women). Oral spironolactone in studies involving female patients only. Topical spironolactone in studies including both sexes.
Who was NOT studied
Men treated with oral spironolactone — feminisation risk prevents this in clinical practice. Children.
What to look for when shopping
Spironolactone is a prescription medication used off-label for hair loss. No formulation is FDA-approved for hair loss. Topical spironolactone is typically compounded.
What research cannot help you decide
Whether topical spironolactone is as effective as oral spironolactone. What the optimal dose or duration is.
Key findings
- 81% of patients receiving oral spironolactone (195 participants) reported hair growth improvement
- Topical spironolactone showed significantly fewer side effects than oral and was suitable for both men and women
- Combining spironolactone with minoxidil consistently produced better results than either treatment alone
- Significant improvement was seen after at least 12 months of oral use at 80–200mg daily
- Oral spironolactone is primarily used in women — feminisation side effects prevent use in men
What they did
Researchers searched four major databases through October 2022 for all human studies evaluating spironolactone for pattern hair loss. 7 articles met inclusion criteria involving 618 patients. Both oral and topical administration were included. A narrative review approach was used without statistical pooling.
What they found
| Comparison | Result | Significant? |
|---|---|---|
| Oral spironolactone — hair growth improvement rate | 81% of 195 patients reported improvement | No |
| Topical spironolactone vs oral — side effects | Significantly fewer side effects with topical | Yes |
| Spironolactone + minoxidil vs monotherapy | Consistently better results with combination | Yes |
What this study does not show
- 1.Whether oral spironolactone is safe for men. Feminisation side effects limit its use to women in clinical practice.
- 2.Whether topical spironolactone is as effective as oral spironolactone in a direct comparison.
- 3.What the optimal dose and duration of topical spironolactone is.
Limitations
- 1.Only 7 studies — a thin evidence base
- 2.Most included studies involved female patients. Male evidence is mainly for topical formulations
- 3.Narrative review without statistical pooling
- 4.Evidence quality varied across included studies
- 5.Topical spironolactone is not commercially standardised
Who funded it
Funded by the National Natural Science Foundation of China (No. 81972954). No conflicts of interest declared.
Used in these articles
Links added as fact-checks and articles citing this study are published.